Abstract

BackgroundSystemic sclerosis (SSc) is a chronic autoimmune-mediated connective tissue disorder. Although the etiology of the disease remains undetermined, SSc is characterized by fibrosis and proliferative vascular lesions of the skin and internal organs. SSc involves the gastrointestinal tract in more than 90 % of patients. Soluble guanylate cyclase (sGC) stimulator is used to treat pulmonary artery hypertension (PAH) and has been shown to inhibit experimental skin fibrosis.MethodsFemale C57BL/6J mice were treated with BLM or normal saline by subcutaneous implantation of osmotic minipump. These mice were sacrificed on day 28 or day 42. Gastrointestinal pathologies were examined by Masson Trichrome staining. The expression of fibrosis-related genes in gastrointestinal tract was analyzed by real-time PCR, and the levels of collagen in the tissue were measured by Sircol collagen assay. To evaluate peristaltic movement, the small intestinal transport (ITR%) was calculated as [dyeing distance × (duodenum − appendix)] − 1 × 100 (%). We treated BLM-treated mice with sGC stimulator or DMSO orally and analyzed them on day 42.ResultsHistological examination revealed that fibrosis from lamina propria to muscularis mucosa in the esophagus was significantly increased in BLM-treated mice, suggesting that BLM induces esophageal hyperproliferative and prefibrotic response in C57BL/6J mice. In addition, the gene expression levels of Col3a1, CCN2, MMP-2, MMP-9, TIMP-1, and TIMP-2 in the esophagus were significantly increased in BLM-treated mice. More severe hyperproliferative and prefibrotic response was observed in the mice sacrificed on day 42 than the mice sacrificed on day 28. The ITR% was found to be significantly lower in BLM-treated mice, suggesting that gastrointestinal peristaltic movement was reduced in BLM-treated mice. Furthermore, we demonstrated that sGC stimulator treatment significantly reduced hyperproliferative and prefibrotic response of esophagus and intestine in BLM-treated mice, by histological examination and Sircol collagen assay.ConclusionsThese findings suggest that BLM induces gastrointestinal hyperproliferative and prefibrotic response in C57BL/6J mice, and treatment with sGC stimulator improves the BLM-induced gastrointestinal lesion.

Highlights

  • Systemic sclerosis (SSc) is a chronic autoimmune-mediated connective tissue disorder

  • We found that BLM treatment increased the distance from the top of the lamina propria to the muscularis mucosa in the esophagus and intestine (Fig. 1c–f)

  • These results confirmed that BLMtreated mice had significantly increased esophageal and intestinal hyperproliferative and prefibrotic response compared with normal saline (NS)-treated mice

Read more

Summary

Introduction

Systemic sclerosis (SSc) is a chronic autoimmune-mediated connective tissue disorder. The etiology of the disease remains undetermined, SSc is characterized by fibrosis and proliferative vascular lesions of the skin and internal organs. Soluble guanylate cyclase (sGC) stimulator is used to treat pulmonary artery hypertension (PAH) and has been shown to inhibit experimental skin fibrosis. Systemic sclerosis (SSc) is a connective-tissue disease of unknown etiology. SSc is characterized by autoimmunity, microvascular impairment, chronic inflammation, and fibrotic changes in various organs [1]. BLM-treated mice are widely accepted as an experimental model of SSc and are mainly used for estimating skin fibrosis. Lee et al recently reported that systemic delivery of BLM using osmotic minipumps caused lung fibrosis from a peripheral lung lesion, which is similar to the lung fibrosis observed in human SSc patients [4]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call